...
首页> 外文期刊>Vaccine >Efficacy of immune sera from human immunoglobulin transgenic mice immunized with a peptide mimotope of Cryptococcus neoformans glucuronoxylomannan
【24h】

Efficacy of immune sera from human immunoglobulin transgenic mice immunized with a peptide mimotope of Cryptococcus neoformans glucuronoxylomannan

机译:用新型隐球菌葡糖醛酸甘露聚糖肽模拟表位免疫的人免疫球蛋白转基因小鼠免疫血清的功效

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The efficacy of antibody mediated immunity against Cryptococcus neoformans has not been established experimentally for human antibodies. Our group has previously shown that immunization with a conjugate consisting of a peptide mimotope of the C. neoformans capsular polysaccharide glucuronoxylomannan (GXM), P13, and diphtheria toxoid (P13-DT) prolonged survival of transgenic mice with human immunoglobulin loci, XenoMouse((R)) mice, which were challenged with a lethal dose of C. neoformans. In the study reported herein, we determined the efficacy of human antibodies in the sera of immunized XenoMouse((R)) mice against C. neoformans in passive transfer experiments in naive BALB/c mice. Survival studies were performed with sera from XenoMouse((R)) mice expressing human IgG2/kappa (G2/k mice) or IgG4/kappa (G4/k mice) that had been immunized with P13-tetanus toxoid (TT)/Alhydrogel with or without CpG, and G2/k mice that had been immunized with P13-DT/Alhydrogel/CpG or Alhydrogel/CpG, obtained on day 7 (early sera) and days 30 or 35-59 (late sera) after primary immunization. Compared to mice receiving sera from G2/k-PBS-treated mice, the survival of naive mice was prolonged by both early and late sera from G2/k-P13-DT/Alhydrogel/CpG-immunized mice, but only late sera from G2/k-P13-TT/Alhydrogel/CpG-immunized mice. Late, but not early sera from G2/k-Alhydrogel/CpG-immunized mice also prolonged survival. For all sera, prolongation of survival was associated with GXM-specific serum IgM. Sera from G2/k mice that received P13-TT without CpG, and all groups of G4/k mice had low to undetectable levels of antibody to GXM and were not protective. Our findings suggest that GXM-specific human IgM may be a functional mediator of protection against C. neoformans.
机译:尚未针对人抗体通过实验确定抗体介导的针对新型隐球菌的免疫效力。我们的研究小组以前表明,使用由新孢梭菌荚膜多糖葡糖醛酸羟甘露聚糖(GXM),P13和白喉类毒素(P13-DT)的肽模拟表位组成的缀合物进行免疫接种可以延长具有人类免疫球蛋白基因座XenoMouse(( R))小鼠,用致死剂量的新孢梭菌攻击。在本文报道的研究中,我们在幼稚BALB / c小鼠的被动转移实验中确定了人类抗体在免疫的小鼠血清中抗新孢子虫的功效。用表达人IgG2 / kappa(G2 / k小鼠)或IgG4 / kappa(G4 / k小鼠)的XenoMouse(R)小鼠的血清进行了存活研究,该小鼠已经用P13-破伤风类毒素(TT)/ Alhydrogel免疫或没有CpG的小鼠,以及在初次免疫后第7天(早期血清)和第30或35-59天(晚期血清)用P13-DT / Alhydrogel / CpG或Alhydrogel / CpG免疫的G2 / k小鼠。与从G2 / k-PBS处理的小鼠接受血清的小鼠相比,G2 / k-P13-DT / Alhydrogel / CpG免疫的小鼠的早期和晚期血清均可延长幼稚小鼠的存活率,但仅从G2的晚期血清可以延长存活率/ k-P13-TT / Alhydrogel / CpG免疫的小鼠。 G2 / k-Alhydrogel / CpG免疫小鼠的晚期但不是早期血清也可以延长生存期。对于所有血清,存活时间的延长与GXM特异性血清IgM有关。来自G2 / k小鼠的血清,该血清接受没有CpG的P13-TT,并且所有G4 / k小鼠组的GXM抗体水平低至无法检测,并且没有保护性。我们的发现表明,GXM特异的人IgM可能是针对新孢梭菌的保护作用的功能性介质。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号